clinical trial was conducted in Karachi,Islamabad and Faisalabad
Karachi, Punjab Province, 74600, Pakistan
NCT Number: NCT04443790
The study was designed to explore an alternative approach to reduce weight in human beings using a polyherbal formulation. A polyherbal formulation named as Obesecure was developed after screening of local medicinal flora. The formulation was further improved after pilot studies and Phase-I Clinical Trials.
Looking for future studies?
Notify Me20 year–50 year
All sexes
Interventional
Phase 2
Karachi, Punjab Province, 74600, Pakistan
Obesity is a common disease of developing countries including Pakistan. Obesity is a risk factor for many diseases which can be life-threatening or making the person unable to perform daily routine work. Obesity is considered a risk factor for different diseases like cardiovascular diseases, hormonal imbalance, infections, malignancies and chest problems. The leptin hormone has appetite suppressing and energy dissipation activity in the body. A screening study on animals was carried out to find out the leptin enhancing medicinal plants from locally available plants in Pakistan. This study was aimed to see the combined effects of the Leptogenic drug Obesecure on weight management.
Patients of age20 to 50 years with BMI more than 25, not taking any anti-obesity drugs one-month prior to start of study were enrolled. The Participants were randomly allocated to receive either Obesecure or placebo twice a day for three months in Shifa-ul-mulk Hospital, PRIEM Health Care Clinic (Pakistan) and Ria Eastern Medicine Clinic (Pakistan).
An acute toxicity study showed no adverse effect of taking Obesecure prior to clinical trials.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Obesecure
Time frame: 3 months
Appetite suppression and energy dissipation
Time frame: 3 Months
weight reduction effects
Hafiz Muhammad Asif
Other
Obesity Control Through Leptogenic Drugs
Acronym: CEOLO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07662538
Body Weight, Digestive System Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT01469962
Body Weight, Digestive System Diseases
Rouen, France
View Trial DetailsNCT05379088
Behavior, Body Weight
Columbus, Ohio, United States
View Trial DetailsNCT02792166
Body Weight, Glucose Metabolism Disorders
Montreal, Quebec, Canada
View Trial Details